Issue link: https://www.e-digitaleditions.com/i/1524818
18 August 2024 Inhalation 19. Brambilla, G., et al., Modulation of aerosol clouds produced by pressurised inhalation aerosols. International Journal of Pharmaceutics, 1999. 186 (1): p. 53-61. 20. Ganderton, D., et al., e formulation and eval- uation of a CFC-free budesonide pressurised metered dose inhaler. Respiratory Medicine, 2003. 97 Suppl D: p. S4-9. 21. Lewis, D.A., et al., Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclo- methasone dipropionate inhalers with and without glycerol as a non-volatile excipient. European Jour- nal of Pharmaceutics and Biopharmaceutics, 2014. 86 (1): p. 31-37. 22. Freiwald, M., et al., Monitoring the initial pul- monary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respiratory Research, 2005. 6 (1): p. 21. 23. Davidson, N., et al., Measurement of the Raman spectra and hygroscopicity of four pharmaceutical aerosols as they travel from pressurised metered dose inhalers (pMDI) to a model lung. International Jour- nal of Pharmaceutics, 2017. 520 (1-2): p. 59-69. 24. Akhuemokhan, P., et al., How to engineer aero- sol particle properties and biopharmaceutical perfor- mance of propellant inhalers. International Journal of Pharmaceutics, 2023. 634: p. 122676. 25. Ivey, J.W., et al., Humidity affects the mor- phology of particles emitted from beclomethasone dipropionate pressurized metered dose inhalers. International Journal of Pharmaceutics, 2017. 520 (1-2): p. 207-215. Lin Zhang, PhD, is a Senior Production Scientist at Ab Initio Pharma, Camperdown, NSW, 2050, Aus- tralia, https://ab-initio-pharma.com. William Glover, PhD, is Chief Operations Officer at Ab Initio Pharma. David A. Lewis, PhD, is Chief Scientific Officer at Oz-UK Limited, Chippenham, Wiltshire, SN14 6RZ, UK, www.oz-uk-labs.com. Robert D. Johnson, BSc, is Chief Operations Officer at Oz-UK Limited. Dan- iel I. Lewis is a Scientist at Oz-UK Limited. Paul M. Young, PhD, is Chief Executive Officer at Ab Initio Pharma. Hui Xin Ong, PhD, corresponding author, is Chief Scientific Officer, Ab Initio Pharma and a Senior Research Fellow in Respiratory Technology, Woolcock Institute of Medical Research, Macquarie Medical School, Macquarie University, Sydney, NSW, 2109, Australia, +614 3338 1575, huixin.ong@ab-initio- pharma.com, www.woolcock.org.au. ticosteroid products. Pharmaceutical Research, 2019. 36 (7): p. 95. 13. Arora, D., et al., In vitro aqueous fluid- capacity- limited dissolution testing of respirable aerosol drug particles generated from inhaler products. Pharma- ceutical Research, 2010. 27 (5): p. 786-795. 14. Buttini, F., et al., Differences in physical chemis- try and dissolution rate of solid particle aerosols from solution pressurised inhalers. International Journal of Pharmaceutics, 2014. 465 (1-2): p. 42-51. 15. Zhu, B., et al., e effect of ethanol on the for- mation and physico-chemical properties of particles generated from budesonide solution-based pressur- ized metered-dose inhalers. Drug Development and Industrial Pharmacy, 2013. 39 (11): p. 1625-1637. 16. Hancock, B.C., et al., What is the true solubility advantage for amorphous pharmaceuticals? Pharma- ceutical Research, 2000. 17 (4): p. 397-404. 17. Riley, T., et al., Challenges with developing in vitro dissolution tests for orally inhaled prod- ucts (OIPs). AAPS PharmSciTech, 2012. 13 (3): p. 978-989. 18. Wong, C.Y.J., et al., Validation of a cell inte- grated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles. International Journal of Pharmaceutics, 2022. 624: p. 122024.